Module manager: Steven Clapcote
Email: S.J.Clapcote@leeds.ac.uk
Taught: Semester 2 (Jan to Jun) View Timetable
Year running 2024/25
First year of a programme in SBMS, or equivalent
BMSC2223
This module is not approved as a discovery module
This module explores the preclinical and clinical processes involved in evaluating whether optimised lead compounds (or other drug types) are likely to be safe and efficacious as a drug. The preclinical stages include evaluating drug efficacy and ADME in in vitro assays and in vivo, in animal disease models. More recent developments have involved human stem cell-derived tissue models and the use of non-mammalian disease models. The module will also cover the stages of clinical trials. Learners will also acquire knowledge of the legal and regulatory aspects associated with the protection, marketing, and monitoring of a drug that has been approved for clinical use.
This module aims to provide an understanding of Pharmacological concepts relating to the preclinical and clinical drug development process. The module will cover the different types of drug that enter development stages (small molecule, antibodies, antisense oligonucleotides, etc) and the challenges and opportunities associated with these. It will cover the stages involved in taking optimised lead compounds (or other drug types) through efficacy and toxicity evaluation, through to clinical trials. Learners will also acquire knowledge of the legal and regulatory aspects associated with the protection and marketing of a drug.
On successful completion of the module students will be able to:
1. Demonstrate an understanding of the applied concepts of preclinical evaluation of drug efficacy and toxicity.
2. Evaluate different types of drug that enter developmental stages.
3. Demonstrate an understanding of the applied concepts clinical evaluation of drug efficacy and toxicity.
4. Evaluate regulatory aspects of drug approval, marketing, and monitoring.
Skills Learning Outcomes
On successful completion of the module students will be able to:
1. Write in a clear, concise, focused and structured manner that is supported by relevant experimental evidence from the published literature
Details of the syllabus will be provided on the Minerva organisation (or equivalent) for the module
| Delivery type | Number | Length hours | Student hours |
|---|---|---|---|
| On-line Learning | 30 | 1 | 30 |
| Workshop | 10 | 2 | 20 |
| Private study hours | 150 | ||
| Total Contact hours | 50 | ||
| Total hours (100hr per 10 credits) | 200 | ||
Short answer problem-solving exercises will be regularly delivered in workshop sessions with formative feedback.
| Assessment type | Notes | % of formal assessment |
|---|---|---|
| Report | Evidence-based report | 50 |
| Total percentage (Assessment Coursework) | 50 | |
Normally resits will be assessed by the same methodology as the first attempt, unless otherwise stated
| Exam type | Exam duration | % of formal assessment |
|---|---|---|
| Online Time-Limited assessment | 2.0 Hrs Mins | 50 |
| Total percentage (Assessment Exams) | 50 | |
Normally resits will be assessed by the same methodology as the first attempt, unless otherwise stated
The reading list is available from the Library website
Last updated: 08/05/2024
Errors, omissions, failed links etc should be notified to the Catalogue Team